Axa
SMMT icon

Axa’s Summit Therapeutics SMMT Stock Holding History

Axa’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-338,000
Closed -$4.36M – 1407
2018
Q1 		$4.36M Buy
338,000
+55,240
+20% +$690K 0.02% 688
2017
Q4 		$3.13M Sell
282,760
-241
-0.1% -$2.69K 0.01% 765
2017
Q3 		$3.55M Sell
283,001
-3,856
-1% -$50K 0.02% 708
2017
Q2 		$3.27M Sell
286,857
-7,309
-2% -$82.3K 0.01% 694
2017
Q1 		$3.9M Buy
294,166
+66
+0% +$763 0.02% 642
2016
Q4 		$2.52M Sell
294,100
-88,954
-23% -$949K 0.01% 717
2016
Q3 		$3.47M Buy
383,054
+349
+0.1% +$2.52K 0.02% 645
2016
Q2 		$2.99M Buy
382,705
+5,500
+1% +$44.8K 0.01% 664
2016
Q1 		$2.57M Hold
377,205
– – 0.01% 708
2015
Q4 		$4.34M Buy
377,205
+1,000
+0.3% +$10.4K 0.02% 598
2015
Q3 		$3.92M Buy
376,205
+83,298
+28% +$998K 0.02% 629
2015
Q2 		$3.09M Hold
292,907
– – 0.01% 693
2015
Q1 		$3.63M Buy
+292,907
New +$3.32M 0.02% 669

Other funds holding SMMT

LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Axa's SMMT Position: Q2 2018 in Review

Axa sold out of Summit Therapeutics (SMMT) in Q2 2018, closing a stake of 338,000 shares — an estimated $4.36M sold.

Axa first reported a position in SMMT in Q1 2015 and held it in 13 quarters. The position peaked at $4.36M in Q1 2018. 17 funds tracked by Wall St. Rank hold SMMT as of Q2 2018.

  • Axa reported no remaining Summit Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Axa sold 338,000 Summit Therapeutics shares in Q2 2018, an estimated $4.36M.
  • Axa first reported a position in Summit Therapeutics in Q1 2015 and held it in 13 quarters.
  • Axa's Summit Therapeutics position peaked at $4.36M in Q1 2018.
  • 17 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2018.

Based on Axa's 13F filing for Q2 2018, filed 13 Aug 2018.